▶ 調査レポート

がん治療の世界市場:販売、インサイト

• 英文タイトル:Global Cancer Treatment Sale, Insights Market Research Report 2019-2025

Straits Researchが調査・発行した産業分析レポートです。がん治療の世界市場:販売、インサイト / Global Cancer Treatment Sale, Insights Market Research Report 2019-2025 / STR-DC009資料のイメージです。• レポートコード:STR-DC009
• 出版社/出版日:Straits Research / 2019年11月28日
• レポート形態:英文、PDF、129ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:製薬
• 販売価格(消費税別)
  Single User(1名様用、印刷不可)¥446,250 (USD4,250)▷ お問い合わせ
  Multi User(5名様用)¥593,250 (USD5,650)▷ お問い合わせ
  Enterprise Price(法人閲覧用)¥761,250 (USD7,250)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートでは、がん治療の世界市場について調査・分析し、調査手法、市場概要、用途別(血液がん、肺がん、大腸がん、前立腺がん、乳がん、子宮頸がん、その他)分析、治療別(化学療法、標的療法、免疫療法、ホルモン療法、その他)分析、エンドユーザー別(病院、専門診療所、がんおよび放射線療法センター)分析、地域別分析、企業概要などを含め次の構成でお届け致します。

・イントロダクション
・調査手法
・市場概要
・がん治療の世界市場:用途別(血液がん、肺がん、大腸がん、前立腺がん、乳がん、子宮頸がん、その他)
・がん治療の世界市場:治療別(化学療法、標的療法、免疫療法、ホルモン療法、その他)
・がん治療の世界市場:エンドユーザー別(病院、専門診療所、がんおよび放射線療法センター)
・がん治療の世界市場:地域別
・企業概要

Global cancer treatment market is expected to reach USD 171,266 million in 2026 from USD 98,069 million in 2018 at a CAGR of 7.3% during the forecast period 2019–2026

Cancer is caused by uncontrolled growth of abnormal cells in distinctive parts of the body, it gets severe with every elevating stage of the disease. Cancer treatment works in the direction of slowing down or eliminating the growth of abnormal cells in the body. Availability of precise and highly effective cancer treatment options with respect to new age technological advancements and minimizing aftereffects of the treatment are expected to drive the overall cancer drug treatment market during the forecast period 2019–2026.

The cancer drug treatment market is expected to witness exponential growth in the coming years as a result of rising prevalence of various cancers across the globe and increasing spending on healthcare. Every year, the number of people suffering from cancer is growing at an unprecedented rate. Globally, 17 million people suffered from cancer in 2018 and it is expected to reach 27.5 million by 2040. Lung cancer is one of the most common type of cancer followed by breast, bowel, and prostate cancer. For instance, 18 million and 17 million cases were found for lung cancer and breast cancer worldwide respectively. In the U.S alone, 3 million men suffered from prostate cancer in 2019. According to the American Cancer Society, in 2014, cancer patients paid approximately USD 4,000 million out-of-pocket for cancer treatment, and roughly USD 87.8 million was spent alone in the U.S. on cancer-related healthcare.

Key Findings
• Targeted therapy segment accounted for the largest revenue share of 42%
• In 2018, lung cancer emerged as the largest application segment in terms of revenue
• Cancer and radiation therapy centers to emerge with the fastest CAGR over the forecast period

Chemotherapy Is the Most Popular Cancer Treatment Option Available In the Cancer Drug Treatment Market
Today, numerous cancer treatments options are available in the cancer drug treatment market and each one has its pros and cons. To study this market in a better way, we have categorized the market by therapy, application, and end user.

By therapy, the cancer drug treatment market is further segmented into chemotherapy, targeted therapy, and immunotherapy. Based on the study, it is witnessed that chemotherapy drugs are highly effective in treating and curing cancer. Numerous chemotherapy drugs are available in the market, and each one of them works on different phases of the cell cycle. Three major categories of chemotherapy drugs are alkylating agents, antimetabolite, and antitumor antibiotic are available for use and they are majorly administered through different routes including oral, intravenous, and topical. In 2016, global chemotherapy treatment generated a revenue of USD 20,608 million and is expected to reach USD 31,210 million by 2026.

Targeted therapy inhibits growth and spread of cancer by interfering or attacking with molecular targets, this ability makes targeted therapy less toxic and exhibit fewer side effects than other cancer treatment types. It can be said that targeted therapy would continue to be the leader in overall treatment for cancer with a robust late-stage drug pipeline, which is accounting for 87% share of the total pipeline for cancer treatment. In 2016, targeted therapy was accounted at USD 37,277 million and is expected to attain a value of USD 59,768 million by 2026.

Immunotherapy works by boosting the body’s immune system to attack specific cancerous cells and eliminate them. It is available in various forms including cancer vaccines, checkpoint inhibitors, cytokines, adjuvants, adoptive cell transfer, and targeted antibodies which are used in different cancer types. As of April 2019, the Food and Drug Administration (FDA) approved immunotherapy as a treatment option for nearly 20 cancer types and cancers with a specific genetic mutation. In 2016, Immunotherapy was accounted for USD 8766 million and is expected generate revenue of USD 17,056 million by 2026.

By end user, the cancer drug treatment market is further segmented into hospitals & clinics and cancer and radiation therapy centers. Hospitals and clinics are leading the global cancer drug treatment market as most of the patients frequently visit the places for diagnosis and treatment of cancer.

Growing Prevalence of Cancer Cases is a Rising Demand for the Cancer Drug Treatment Market
North America is dominating the global treatment markets. U.S. is the leading cancer drug treatment market as a result of developed healthcare infrastructure and technologically advanced cancer treatment services, presence of major players in the country, and ongoing research and development for the improvement of treatment options.

It has been found that a huge population is suffering from cancer in the region. For instance, the U.S., Canada, and Mexico are housing over 2 million, 177,880, and 190,000 cancer cases respectively. Moreover the total revenue of the U.S., Canada, and Mexico was accounted for USD 32,011 million, USD 5659 million, and USD 828 million respectively in 2016, which is expected to reach USD 50,666 million, USD 8438 million, and USD 1393 million respectively by 2026.

In the U.S, high prevalence of various cancers, including skin cancer, lung cancer, breast cancer, and ovarian cancer, among others is driving the market growth. According to the National Cancer Institute, in 2018, about 1,735,350 new cases of cancer were diagnosed alone in the U.S. with an incidence rate of 439.2 cases per 100,000 people, and near about 609,640 people died from the disease.

In Canada, more than 206,200 new cases were diagnosed with cancer in 2005 and the number is expected grow by 80% by 2030, Canadian Cancer Society. Similarly, over 190,667 new cases of cancer were diagnosed in Mexico. Out of which, breast, prostate, colorectal, thyroid, cervix uterus, and other types of cancer accounted for 14.3%, 13.1%, 7.8%, 6.4%, 4.1%, and 54.3% share of the market respectively, WHO.

Prominent Players Active in the Market
Some of the prominent players in the global cancer treatment market are F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Johnson & Johnson, Celgene Corporation, Astellas Pharma, Inc., Pfizer, Inc., Novartis AG, Merck KGaA, and Eli Lilly, AstraZeneca plc, Bayer AG, and Takeda Pharmaceutical Company Limited.

Our Report Covers
• Historical inferences, findings & analysis of the market from 2016 to 2018
• Projections and performance forecast analysis for the future from 2019 to 2026
• Production and consumption point of view (POV) analysis
• Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
• Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability, and prospects

レポート目次

TABLE OF CONTENTS
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Cancer Treatment Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
3.6 Pipeline Analysis
3.7 Cost Effective Analysis
3.8 Top Selling Chemotherapy Drugs, 2017, USD Million
3.9 Top selling cancer drugs, 2018, USD Million
4 By Application Overview
4.1 Introduction
4.1.1 Market Size & Forecast (Value)
4.2 Blood Cancer
4.3 Lung Cancer
4.4 Colorectal Cancer
4.5 Prostate Cancer
4.6 Breast Cancer
4.7 Cervical Cancer
4.8 Others
5 By Therapy Overview
5.1 Introduction
5.1.1 Market Size & Forecast (Value)
5.2 Chemotherapy
5.3 Targeted Therapy
5.4 Immunotherapy
5.5 Hormonal Therapy
5.6 Others
6 End Users
6.1 Introduction
6.1.1 Market Size & Forecast (Value)
6.2 Hospitals
6.3 Specialty Clinics
6.4 Cancer & Radiation Therapy Centres
7 Regional Overview
7.1 Introduction
7.1.1 Market Size & Forecast (Value)
7.2 America
7.2.1 North America
7.2.1.1 U.S.
7.2.1.1.1 By Treatment
7.2.1.1.2 By Therapy
7.2.1.1.3 By End Users
7.2.1.2 Canada
7.2.1.2.1 By Treatment
7.2.1.2.2 By Therapy
7.2.1.2.3 By End Users
7.2.1.3 Mexico
7.2.1.3.1 By Treatment
7.2.1.3.2 By Therapy
7.2.1.3.3 By End Users
7.2.4 Latin America
7.2.4.1 By Treatment
7.2.4.2 By Therapy
7.2.4.3 By End Users
7.3 Europe
7.3.1 Market Size & Forecast (Value)
7.3.2 Germany
7.3.2.1 By Treatment
7.2.2.2 By Therapy
7.3.2.3 By End Users
7.3.3 France
7.3.3.1 By Treatment
7.3.3.2 By Therapy
7.3.3.3 By End Users
7.3.4 U.K.
7.3.4.1 By Treatment
7.3.4.2 By Therapy
7.3.4.3 By End Users
7.3.5 Italy
7.3.5.1 By Treatment
7.3.5.2 By Therapy
7.3.5.3 By End Users
7.3.6 Spain
7.3.6.1 By Treatment
7.3.6.2 By Therapy
7.3.6.3 By End Users
7.3.7 Rest of Europe
7.3.7.1 By Treatment
7.3.7.2 By Therapy
7.3.7.3 By End Users
7.4 Asia-Pacific
7.4.1 Market Size & Forecast (Value)
7.4.2 Japan
7.4.2.1 By Treatment
7.4.2.2 By Therapy
7.4.2.3 By End Users
7.4.3 China
7.4.3.1 By Treatment
7.4.3.2 By Therapy
7.4.3.3 By End Users
7.4.4 Australia
7.4.4.1 By Treatment
7.4.4.2 By Therapy
7.4.4.3 By End Users
7.4.5 India
7.4.5.1 By Treatment
7.4.5.2 By Therapy
7.4.5.3 By End Users
7.4.6 South Korea
7.4.6.1 By Treatment
7.4.6.2 By Therapy
7.4.6.3 By End Users
7.4.7 Rest of Asia-Pacific
7.4.7.1 By Treatment
7.4.7.2 By Therapy
7.4.7.3 By End Users
7.5 Middle East & Africa
7.5.1 Market Size & Forecast (Value)
7.5.2 Saudi Arabia
7.5.2.1 By Treatment
7.5.2.2 By Therapy
7.5.2.3 By End Users
7.5.3 South Africa
7.5.3.1 By Treatment
7.3.3.2 By Therapy
7.5.3.3 By End Users
7.5.4 Kuwait
7.5.4.1 By Treatment
7.5.4.2 By Therapy
7.5.4.3 By End Users
7.5.5 Rest of Middle East & Africa
7.5.5.1 By Treatment
7.5.5.2 By Therapy
7.5.5.3 By End Users
8. Company Profile
8.1 F. Hoffmann-La Roche AG
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Recent Developments
8.1.4 Product Portfolio
8.2 Bristol-Myers Squibb Company
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Recent Developments
8.2.4 Product Portfolio
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Recent Developments
8.3.4 Product Portfolio
8.4 Johnson & Johnson
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Recent Developments
8.4.4 Product Portfolio
8.5 Celgene Corporation
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Recent Developments
8.5.4 Product Portfolio
8.6 Astellas Pharma, Inc.
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Recent Developments
8.6.4 Product Portfolio
8.7 Pfizer, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Recent Developments
8.7.4 Product Portfolio
8.8 Novartis AG
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Recent Developments
8.8.4 Product Portfolio
8.9 Merck KGaA
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Recent Developments
8.9.4 Product Portfolio
8.10 Eli Lilly, AstraZeneca plc
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Recent Developments
8.10.4 Product Portfolio
8.11 Bayer AG
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Recent Developments
8.11.4 Product Portfolio
8.12 Takeda Pharmaceutical Company Limited.
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 Recent Developments
8.12.4 Product Portfolio

LIST OF TABLES
TABLE 1 Top Selling Chemotherapy Drugs, 2017, ($Million)
TABLE2 Top Selling Cancer Drugs, 2018, ($Million)
TABLE 3 Global Cancer Treatment Market Share, By Application, 2016 – 2026 ($Million)
TABLE 4 Blood Cancer Treatment Market Share, By Region, 2016 – 2026 ($ Million)
TABLE 5 Lung Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 6 Colorectal Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 7 Prostate Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 8 Breast Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 9 Cervical Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 10 Others Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 11 Global Cancer Treatment Market Share, By Therapy, 2016 – 2026 ($Million)
TABLE 12 Chemotherapy Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 13 Targeted Therapy Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 14 Immunotherapy Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 15 Hormonal Therapy Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 16 Others Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 17 Global Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 18 Hospitals Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 19 Specialty Clinics Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 20 Cancer & Radiation Therapy Centers Cancer Treatment Market Share, By Region, 2016 – 2026, ($ Million)
TABLE 21 Global Cancer Treatment Market Share Value, 2016 – 2026 ($Million)
TABLE 22 America Cancer Treatment Market Share Value, By Country, 2016 – 2026 ($Million)
TABLE 23 America Cancer Treatment Market Share Value, By Treatment, 2016 – 2026 ($Million)
TABLE 24 America Cancer Treatment Market Share Value, By End Users, 2016 – 2026 ($Million)
TABLE 25 U.S. Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 26 U.S. Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 27 Canada Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 28 Canada Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 29 Mexico Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 30 Mexico Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 31 South America Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 32 South America Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 33 Europe Cancer Treatment Market Share Value, By Country, 2016 – 2026 ($Million)
TABLE 34 Europe Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 35 Europe Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 36 Germany Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 37 Germany Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 38 France Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 39 France Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 40 UK Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 41 UK Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 42 Italy Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 43 Italy Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 44 Spain Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 45 Spain Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 46 Rest of Europe Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 47 Rest of Europe Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 48 Asia-Pacific Cancer Treatment Market Share Value, By Country, 2016 – 2026 ($Million)
TABLE 49 Asia-Pacific Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 50 Asia-Pacific Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 51 Japan Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 52 Japan Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 53 China Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 54 China Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 55 Australia Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 56 Australia Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 57 India Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 58 India Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 59 South Korea Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 60 South Korea Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 61 Rest of Asia-Pacific Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 62 Rest of Asia-Pacific Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 63 MEA Cancer Treatment Market Share Value, By Country, 2016 – 2026 ($Million)
TABLE 64 MEA Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 65 MEA Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 66 Saudi Arabia Cancer Treatment Market Share, By Treatment, 2016-2025 ($Million)
TABLE 67 Saudi Arabia Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 68 South Africa Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 69 South Africa Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 70 Kuwait Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 71 Kuwait Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)
TABLE 72 Rest of LAMEA Cancer Treatment Market Share, By Treatment, 2016 – 2026 ($Million)
TABLE 73 Rest of LAMEA Cancer Treatment Market Share, By End Users, 2016 – 2026 ($Million)

List of Figures
FIGURE 1 Global Cancer Treatment Market Overview
FIGURE 2 Value Chain Analysis
FIGURE 3 Bargaining Power of Suppliers
FIGURE 4 Bargaining Power of Buyers
FIGURE 5 Threat of Substitutes
FIGURE 6 Threat of New Entrants
FIGURE 7 Competitive Rivalry
FIGURE 8 Global Cancer Treatment Market Share Analysis, 2018
FIGURE 9 Global Cancer Treatment Market, 2016-2026
FIGURE 10 Americas Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 11 North America Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 12 U.S. Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 13 Canada Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 14 Mexico Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 15 South America Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 16 Europe Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 17 Germany Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 18 France Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 19 UK Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 20 Italy Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 21 Spain Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 22 Rest of Europe Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 23 Asia Pacific Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 24 Japan Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 25 China Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 26 Australia Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 27 India Global Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 28 South Korea Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 29 Rest of Asia-pacific Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 30 MEA Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 31 Kuwait Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 32 Saudi Arabia Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 33 South Africa Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 34 Rest of MEA Cancer Treatment Market Share, 2016-2026 ($Million)
FIGURE 35 F. Hoffmann-La Roche AG.: Revenue Analysis, ($ million)
FIGURE 36 F. Hoffmann-La Roche AG.: Segment Revenue 2017 (%)